172 related articles for article (PubMed ID: 21051918)
1. FOXP3+ regulatory T cells and tumoral indoleamine 2,3-dioxygenase expression predicts the carcinogenesis of intraductal papillary mucinous neoplasms of the pancreas.
Kobayashi N; Kubota K; Kato S; Watanabe S; Shimamura T; Kirikoshi H; Saito S; Ueda M; Endo I; Inayama Y; Maeda S; Nakajima A
Pancreatology; 2010; 10(5):631-40. PubMed ID: 21051918
[TBL] [Abstract][Full Text] [Related]
2. Indoleamine 2,3-dioxygenase affects the aggressiveness of intraductal papillary mucinous neoplasms through Foxp3+CD4+CD25+ T cells in peripheral blood.
Ikemoto T; Shimada M; Komatsu M; Yamada S; Saito Y; Mori H; Morine Y; Imura S; Bando Y; Utsunomiya T
Pancreas; 2013 Jan; 42(1):130-4. PubMed ID: 22722263
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.
Hiraoka N; Onozato K; Kosuge T; Hirohashi S
Clin Cancer Res; 2006 Sep; 12(18):5423-34. PubMed ID: 17000676
[TBL] [Abstract][Full Text] [Related]
4. Minimally invasive intraductal papillary-mucinous carcinoma of the pancreas: clinicopathologic study of 104 intraductal papillary-mucinous neoplasms.
Nara S; Shimada K; Kosuge T; Kanai Y; Hiraoka N
Am J Surg Pathol; 2008 Feb; 32(2):243-55. PubMed ID: 18223327
[TBL] [Abstract][Full Text] [Related]
5. Intraductal papillary mucinous neoplasms of the pancreas: an analysis of protein expression and clinical features.
Nishikawa N; Kimura Y; Okita K; Zembutsu H; Furuhata T; Katsuramaki T; Kimura S; Asanuma H; Hirata K
J Hepatobiliary Pancreat Surg; 2006; 13(4):327-35. PubMed ID: 16858545
[TBL] [Abstract][Full Text] [Related]
6. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis.
Hiraoka N; Yamazaki-Itoh R; Ino Y; Mizuguchi Y; Yamada T; Hirohashi S; Kanai Y
Gastroenterology; 2011 Jan; 140(1):310-21. PubMed ID: 20955708
[TBL] [Abstract][Full Text] [Related]
7. Mural nodule in branch duct-type intraductal papillary mucinous neoplasms of the pancreas is a marker of malignant transformation and indication for surgery.
Akita H; Takeda Y; Hoshino H; Wada H; Kobayashi S; Marubashi S; Eguchi H; Tanemura M; Mori M; Doki Y; Nagano H
Am J Surg; 2011 Aug; 202(2):214-9. PubMed ID: 21376305
[TBL] [Abstract][Full Text] [Related]
8. CD4/CD8 + T cells, DC subsets, Foxp3, and IDO expression are predictive indictors of gastric cancer prognosis.
Li F; Sun Y; Huang J; Xu W; Liu J; Yuan Z
Cancer Med; 2019 Dec; 8(17):7330-7344. PubMed ID: 31631566
[TBL] [Abstract][Full Text] [Related]
9. Expression of indoleamine 2,3-dioxygenase and infiltration of FOXP3+ regulatory T cells are associated with aggressive features of papillary thyroid microcarcinoma.
Ryu HS; Park YS; Park HJ; Chung YR; Yom CK; Ahn SH; Park YJ; Park SH; Park SY
Thyroid; 2014 Aug; 24(8):1232-40. PubMed ID: 24742251
[TBL] [Abstract][Full Text] [Related]
10. Clinical role of Notch signaling pathway in intraductal papillary mucinous neoplasm of the pancreas.
Ikemoto T; Sugimoto K; Shimada M; Utsunomiya T; Morine Y; Imura S; Arakawa Y; Kanamoto M; Iwahashi S; Saito Y; Yamada S
J Gastroenterol Hepatol; 2015 Jan; 30(1):217-22. PubMed ID: 25041344
[TBL] [Abstract][Full Text] [Related]
11. Pdcd4 expression in intraductal papillary mucinous neoplasm of the pancreas: its association with tumor progression and proliferation.
Hayashi A; Aishima S; Miyasaka Y; Nakata K; Morimatsu K; Oda Y; Nagai E; Oda Y; Tanaka M; Tsuneyoshi M
Hum Pathol; 2010 Nov; 41(11):1507-15. PubMed ID: 20656320
[TBL] [Abstract][Full Text] [Related]
12. Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.
Speeckaert R; Vermaelen K; van Geel N; Autier P; Lambert J; Haspeslagh M; van Gele M; Thielemans K; Neyns B; Roche N; Verbeke N; Deron P; Speeckaert M; Brochez L
Eur J Cancer; 2012 Sep; 48(13):2004-11. PubMed ID: 22033321
[TBL] [Abstract][Full Text] [Related]
13. Expression of indoleamine 2,3-dioxygenase in metastatic pancreatic ductal adenocarcinoma recruits regulatory T cells to avoid immune detection.
Witkiewicz A; Williams TK; Cozzitorto J; Durkan B; Showalter SL; Yeo CJ; Brody JR
J Am Coll Surg; 2008 May; 206(5):849-54; discussion 854-6. PubMed ID: 18471709
[TBL] [Abstract][Full Text] [Related]
14. CD44v6 expression in intraductal papillary mucinous neoplasms of the pancreas.
Miyasaka Y; Nagai E; Ohuchida K; Nakata K; Hayashi A; Mizumoto K; Tsuneyoshi M; Tanaka M
Pancreas; 2010 Jan; 39(1):31-5. PubMed ID: 19952968
[TBL] [Abstract][Full Text] [Related]
15. MUC1 overexpression is the most reliable marker of invasive carcinoma in intraductal papillary-mucinous tumor (IPMT).
Ueda M; Miura Y; Kunihiro O; Ishikawa T; Ichikawa Y; Endo I; Sekido H; Togo S; Shimada H
Hepatogastroenterology; 2005; 52(62):398-403. PubMed ID: 15816444
[TBL] [Abstract][Full Text] [Related]
16. Increased K-ras mutation and expression of S100A4 and MUC2 protein in the malignant intraductal papillary mucinous tumor of the pancreas.
Jang JY; Park YC; Song YS; Lee SE; Hwang DW; Lim CS; Lee HE; Kim WH; Kim SW
J Hepatobiliary Pancreat Surg; 2009; 16(5):668-74. PubMed ID: 19412570
[TBL] [Abstract][Full Text] [Related]
17. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors.
Hirono S; Tani M; Kawai M; Ina S; Nishioka R; Miyazawa M; Fujita Y; Uchiyama K; Yamaue H
Arch Surg; 2009 Apr; 144(4):345-9; discussion 349-50. PubMed ID: 19380648
[TBL] [Abstract][Full Text] [Related]
18. Characterization of CD24 expression in intraductal papillary mucinous neoplasms and ductal carcinoma of the pancreas.
Ikenaga N; Ohuchida K; Mizumoto K; Yu J; Kayashima T; Hayashi A; Nakata K; Tanaka M
Hum Pathol; 2010 Oct; 41(10):1466-74. PubMed ID: 20619441
[TBL] [Abstract][Full Text] [Related]
19. The role of the DNA damage checkpoint pathway in intraductal papillary mucinous neoplasms of the pancreas.
Miyasaka Y; Nagai E; Yamaguchi H; Fujii K; Inoue T; Ohuchida K; Yamada T; Mizumoto K; Tanaka M; Tsuneyoshi M
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4371-7. PubMed ID: 17671118
[TBL] [Abstract][Full Text] [Related]
20. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells.
Lee SY; Choi HK; Lee KJ; Jung JY; Hur GY; Jung KH; Kim JH; Shin C; Shim JJ; In KH; Kang KH; Yoo SH
J Immunother; 2009 Jan; 32(1):22-8. PubMed ID: 19307990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
